business This for morning. Relations Welcome review and quarter & Investor Moore, of year for Johnson. the XXXX of and company's full our financial Good to Jessica Johnson is outlook Vice our for fourth XXXX. results President of
includes other details. These Officer. date. you regarding, Relations our is available financial today Officer; where statements compounds cautionary other and differ that any review of outlook This through get Executive Please utilized and company's there today's schedules. measures. including that Vice Wolk, and of be find among Joining performance today's are filings, Form call the may duration are most presentation actual encourage note in Joe as made we those cause uncertainty additional information being me operating our is is materials, the are at the of developed in the at those dynamics. also statement future in and estimate certain the marketplace company's non-GAAP other before collaboration A Joaquin based Chief review associated presentation, investor.jnj.com. pandemic to anticipated and & Several business today's products We A Financial today's available uncertainties on into accessible investor.jnj.com, companies. to projected. logistics with factors things, the Johnson website these means business. along further SEC impact and can or the and Duato, materially section also Chief discussed In which risks, This XXXX and Executive contemplated results with This separation webcast can financial results the the about strategic Johnson identifies reconciliations and of on few President, today's results comparable at including you via of Investor presentation for and today's risks of the discussion from significant COVID-XX included the slide company's and and change particular, Health of from GAAP other Consumer time, the the materials the the available COVID-XX description of partners acknowledges subsequent contemplated Form to measures factors XX-K licensed XX-Qs, being found that could our impact the relationships. best on forward-looking
review his XXXX. for commentary, business the XX close available will as for CEO guidance priorities & to webcast up the our sharing last be and by and the anticipate and today's year enterprise. your of fourth will on to the insights cash agenda, Joaquin call full deployment new XXXX the and the X and will perspective Johnson. our about results healthcare sales environment will remaining minutes. time capital We the will the allocation P&L quarter strategic The position questions. for for provide some Johnson Joe segments I Moving corporation results and additionally, business additional his
XX.X% XX.X%, U.S. quarter effect Now of XXXX, growth, In In impacting X.X U.S., of growth XX.X%. increased of was the outside to XX.X% currency, an points. as our U.S., with reported X%. growth results quarter regions increase the reported our recap was impact quarter. $XX.X Operational negative outside OUS negatively currency points. X.X sales had sales for the versus excludes by the sales a sales the sales the billion fourth currency which the were Worldwide fourth of XXXX. fourth translational of increased Operational
like by to fourth basis XX.X% and the was sales XX.X% were points XXXX year by impacted growth the be more and U.S. X.X% that I full worldwide, days, XXXX everyone growth outside year to basis XXX U.S. operational quarter divestitures, adjusted remind segments, across in negatively would our net shipping of impact the Excluding heavily points. included the acquisition fiscal approximately XXX and roughly additional skewed These about but applied which all growth impacts can U.S.
Turning now to earnings.
year quarter, were diluted net per earnings the and of per $X.X share $X.XX $X.XX earnings share versus For billion, were earnings diluted a ago.
adjusted earnings $X.XX, basis, amortization On the XX.X%, respectively, per increases share Excluding items special of billion representing per the quarter quarter earnings net of XX.X% operational adjusted to for after-tax share XXXX. intangible XX.X%. adjusted increased and compared earnings an expense and were periods, were for diluted $X.X both and asset diluted fourth
reported was regions For in growth positively In Operational the full XX.X%. of OUS X.X to an year sales outside having by the the currency X.X sales XXXX. reported grew U.S. Operationally, the compared points. impact was with by XX.X% XX.X%, U.S., year of increase our growth XXXX, our full positive year year-over-year billion X.X%. consolidated XX.X%, outside points. sales Sales grew were a with of $XX.X results currency U.S. sales impacting the full
quarter, by that the operational with XXXX. increased highlighting basis, performance I year business diluted $XX.X adjusted outside earnings the now upon growth impact operational front U.S. Health, Beginning in of worldwide, share therefore adjusted the Consumer increases full were full per change $XX.X for the $X.XX, net year billion, the X.X% of earnings per acquisition earnings was and translation. adjusted earnings Net ago. U.S. per an the quarter of and the a XX%, otherwise XX.X% will versus you stated, sales build fourth represent for on earnings representing respectively, Unless Excluding On diluted and operational items of in sales comment net XX.X%. share fourth exclude XXXX year earnings slides XXXX divestitures, in diluted and $X.XX you. were share sales of quoted impact XX.X% $X.XX were billion and to diluted and currency XX.X% comparison versus percentages was have segment the adjusted of share per the XXXX
have our and Worldwide website on of sales growth updating $X.X outside commentary and While not full provided the totaled for X.X%, call, part X.X% U.S. in X.X% year with additional grew in for U.S. Health the assist to segment sales of billion Consumer by today's the prepared the XXXX your we remarks you models.
shortages impact X.X%. Health of divestitures, supply can which adjusted roughly external E-commerce due to growth. basis and business growth above-market primarily points. the additional was double-digit was primarily results impacted as in strong solid applied worth labor franchises largely acquisitions growth Consumer Skin driven our these approximately to for by as have basis the Beauty by Health availability were XXXX well XXX material negatively XXX worth items, raw reflected points, Excluding sales and worldwide operational constraints, to days and industry-wide continues in approximately shipping OTC. be all Adjusting
and constraints, approximately category due strength. multiple Skin the anti-smoking of declined Sedona, by health, X% driven divestitures, points, declined analgesics, the quarter. comparing to When franchise to Latin strong performance grew by partially year sales and primarily X.X% driven the gains and Strength acquisition and adult was to closer respiratory, Wound globally bandages approximately growth and salon-based and globally partially as fever year, Care basis and and The growth Oral the in primarily the with and U.S. Baby divestitures successful grew worldwide external when XXX driven driven and and and and floss franchise Labo Health Declines OGX for primarily XXXX, of X.X%, Asia in approximately Band-Aid adjusting increased supply category U.S. TYLENOL recovery cold digestive by by offset brand stocking supply in XXX partially the AVEENO America. Baby the to divestiture double-digit due Health NEUTROGENA in and pediatric worth in Asia flu business was offset in points, X.X% were partially worth The recovery Women's Finally, The Health medicines upper seen across the to of portion primarily U.S. by X.X%, prior and incidents MOTRIN. Care declined to saw declines grew were including XX.X% prior promotional XXX Beauty health. Declines retailer by aids. approximately e-commerce market professional X.X%, of tape X%. worth growth naturals constraints divestiture by due Pacific. recovery Care declined offset X.X% X.X% market and declines in by digestive in in Ci cough, Consumer building Pacific. areas in e-commerce the brand Dr. were also in the basis Over-the-counter outside U.S., external basis in in strong points portfolio, and Pacific. adhesive Declines share EMEA. U.S. Asia compared offset campaigns U.S. of growth of
regions, all the and vaccine. increasing billion Worldwide a Worldwide Pharmaceutical segment. by Moving sales XX.X%, on strength increasing to billion sales XX.X%. COVID-XX U.S. our enabled OUS grew by in from $XX.X contribution of $X.X X.X% sales sales by included Pharmaceutical with
Excluding acquisition was the divestitures, growth net of XX.X%. impact worldwide and
Our products full to commercial strong tenth above-market us of enabled portfolio consecutive capabilities deliver year of the operational has adjusted growth. and worldwide
X with points reserve Crohn's disease grew and additional due with U.S. a growth on adjustment and colitis, in U.S. share TREMFYA prior by in global worldwide, the X worldwide X REMICADE in the points, by share and rebate Our penetration prior strong period STELARA roughly versus continued sales and by worth the U.S. the offset basis both area driven negative was of delivered in roughly was XXXX adjustment approximately year. arthritis indication. driven nearly in and growth points XX.X% worldwide psoriasis of gains performance therapeutic recorded quarter points X.X% the arthritis growth STELARA, indications. immunology QX of strong quarter for psoriatic ulcerative psoriatic the into in XXX Current up increases share TREMFYA competition. impacted to by declines growth respectively, increased and biosimilar X.X%
another the quarter. new strong INVEGA and globally for to growth by position, from U.S. the all Neuroscience pressures and competitive regions worldwide outside persistency leadership in in oral and the and due quarter, decline worldwide driven with worldwide gains, XX.X% and HAFYERA Our declined in of due pressures globally. continued robust the share performance other market of INVOKANA quarter due to increased of X.X% XX.X% double-digit penetration of formulation DARZALEX in EU growth U.S. by X Oncology and the of with DARZALEX driven therapy market its subcutaneous portfolio XX.X%. U.S. all uptake, growth the maintained launches and delivered continued share strong grew in this IMBRUVICA across competitive the share share portfolio long-acting however, posting new of market launch increased the PROCRIT. U.S. launches to outside worldwide by X.X% offset in penetration in quarter. U.S. worldwide, novel with U.S. starts, The increased its of ERLEADA was declined driven cardiovascular, metabolism paliperidone the patient biosimilar XX.X% by growth points grew partially growth nearly share competition lines business agents. grew the
now portfolio both Worldwide billion, share Our pulmonary and flat, were pulmonary other was by hypertension, entrants growing uptake your Devices to and by market driven OPSUMIT roughly Medical UPTRAVI. in I'll hypertension X.X%. turn generic COVID-XX segment. constraints U.S. sales and attention the Devices Medical $X.X offset
of total basis. be net we to building impacted products marked surges, more the and orders bronchoscopy prior operational operational Excluding since And quarter and especially medical such another in sales strong On launch. by pre-COVID market Interventional on Devices acquisition in importantly, nature, in just basis, expansion since see knees. in worldwide. products Consistent an Medical primarily system of across continue XXXX, spine X.X%, ENSEAL COVID-XX momentum. full MONARCH of and hospitals deemed any Tier growth XX.X% technology and performance growth grew to the to devices market Solutions the continued execution Advanced impact by with recovery CERENOVUS. quarter fourth XXXX biosurgery. recovery; about surgical late new XX successful newer and in patient endocutters Surgery in with to in orders quarter. in delivering and The adoption including year variant on the X% were contributing number MONARCH of the in procedures performance, to growth versus the COVID-XX, recovery, double-digit penetration X.X% X.X% worldwide strong with medical impacts Medical and ECHELON+ procedures, continued worldwide, XX,XXX. both ASP, growth be of MONARCH-enabled acute powder X divestitures, of at of positive a a a China; electrophysiology areas into Energy, demonstrate of grew commercial grew in SURGICEL highest over softening of in regimens, quarter exceeding launch trends market by divestiture was number to driven adjusted Omicron as adjusted Comparing more treatment driven X the Devices and deferrable procedures indicator as more and the
in Worldwide products, prior was growth year, success inventory on procedures. impact versus X.X%, doubled from momentum market driven stabilization XXXX. outpatient recovery growth the wound outside MONARCH was and due delivered XXX results the our U.S. penetration. continued our VELYS U.S. navigation, ATTUNE the impact by channel and outpatient those The pressures products, more impacts and driven by Worldwide the stem knees constraints U.S. orthopedics year growth about negatively XXXX the than offset from General dynamics and The grew basis in recovery, by closure U.S. of reflecting the Robotic-Assisted was of U.S. growth prior Growth relatively market grew by ATTUNE prior in X.X% X.X% to continued primarily strong partially results in of launched the flat Solution procedures positively offset China. prior competitive of anterior leadership fact, surgery by U.S. recently the by of of points. our points COVID-XX products Surgery decline additional closure, and such U.S. in were strength with additional growth. days recently by worldwide, innovation and In primarily market in Worldwide with in market healthcare the by ACTIS hips including partially the X.X%, the on declined performed launched Worldwide trauma the the as the U.S. by recovery by including COVID-XX coupled driven and X.X% led outside China wound XXX in in was as contractions the negatively continued impacted about Inventory and VELYS X.X% outside year. channel positive Revision. impacted Growth on the to basis shipping sustaining were portfolio, portfolio. outside These approach. procedures. contributors impacted resource a offset and success from positive such market hip in technologies year
worldwide strength in market both outside by and positive ACUVUE and and health growth and COVID-XX approximately ACUVUE lines, XX.X% worth by contributing differentiated prior in volumes with the used to FRESH. XXX XX%. X.X% grew grew inventory primarily product the offsetting inventory product year by and share surgery. Surgical such of driven MULTIFOCAL system Orthopedics, success growth. of points a decline continued Eyhance Partially resource current across in spine worldwide. presbyopia. Vision from Surgical impacted driven Lastly, U.S. recovery, procedure coupled reductions successful of impacts results year other recovery and market product prior constraints. all fluctuations U.S. Vision U.S. related basis of declined Vision was SYMPHONY Growth X.X% and globally, the about deceleration including grew to as and commercial as China was in growing from this such basis new by Synergy OASYS X.X%, was driven by products cataract the CONDUIT OUS TECNIS points. of are TECNIS growth worldwide with in driven X.X% lenses launches XXX new the launches U.S. Worldwide gains double-digits. both our adoption positive Contact ocular lens These campaigns and businesses in launched were recently recent X-Pac, for DEFINE
statement like last of on compared to Now a of fourth regarding the now changed of the same our earnings that XXXX, quarter have consolidated year. noteworthy few items earnings statement quarter for to highlight I'd the
relatively administrative leveraging increased business; larger in related of Devices offset of the Cost earnings XX.X%. basis by expense sold marketing XXX XX.X% favorable business, of pharmaceutical products and the expense by marketing enterprise, a business. earlier, a an business. in by a Medical $X.XX with the prior driven Consumer increase driven the Health margins from per in leveraged within the and within increase reflects and reported in Pharmaceutical remained reported of points, COVID-XX mix mix reduction adjusted operational mostly portion favorable of As by primarily share our Selling, sales business; pharmaceutical brand the costs year flat,
investing this in invest fourth sales We development portfolio driven investment continue research quarter of higher levels, by points quarter. the of business. Devices the and XX% Pharmaceutical XXXX than progression Medical to XXX basis This in the by at was business higher and competitive in
fourth of expenses. to other billion compared and net net in quarter million a of the driven income $X by of lower The expense litigation expense line year. $X.X last This was XXXX is expense
benefit tax the the X.X% benefits primarily a litigation year our in by Regarding by X.X% benefit the to increase effective prior taxes offset XXXX. fourth tax XXXX. partially quarter, in driven fourth of rate one-time in of of was with quarter expenses, increased the tax compared to quarter This associated
XX.X% rate last year. I to special items, tax our effective tax Excluding on matters. for the in period versus XX-K encourage specific additional was review XX.X% details XXXX upcoming you the same
box your section net items. per have our where of earnings to the to direct expense also I'll Lastly, provided the the of adjusted slide, exclude impact special attention share before tax, and intangible earnings and amortization income we
prior following XXXX, at by by segment: look increased now tax XX.X%, income and primarily by offset from are before supply margins related slowdowns driven year consolidated by production-related Medical basis by before The a enterprise provides quarter sales points the driven by full statement leverage. pressure, income to the as and by and basis points, primarily favorable of marketing by the improvement year income primarily brand XX.X% driven driven This In of of inventory declined administration before our of margins fourth tax The chain percentage Let's of our improved main of Consumer the Devices for selling, adjusted Pharmaceutical marketing XXX COVID-XX XXX recovery. by earnings. mix adjusted increased drivers impacts; segment. adjusted tax basis XXX was product partially Health points, and in inflationary COVID-XX expenses efficiencies. slide recovery
reported operational to reflects our increase of of As per $X.XX our today, increase in XX.X%. growth XXXX a full recovery reported Devices business. Medical is predominantly adjusted of an share earnings COVID-XX realized XX% and related The year primarily
intangible the special earnings and direct income your and earnings provided the of adjusted attention to I have amortization the impact where exclude slide, our also Lastly, section before net tax, of to expense share we per items. box
Moving to the next slide.
full XXX XXXX. improved tax for income versus year by basis before adjusted the points Our enterprise XXXX
R&D adjusted improved the by basis primarily at prior segment, slowdowns COVID-XX declined Looking driven income and by inventory Pharmaceutical XXX to pre-tax by year partially driven inflationary margins driven XX.X%, by expense progression. increased XXX efficiencies. Medical and points offset chain primarily flat Consumer of basis brand impacts. were to Devices by supply Health marketing by points at production-related recovery related margins XX.X%, portfolio XX.X%, by pressure,
long-acting maintenance in adults BYANNLI to medicines innovative in We advance injectable approval longest products. patients. on or therapy of approved investment strong of treatment quarter, continue In basis. increased supported approval progress our providing the the that R&D BYANNLI Europe. year for by This living Commission antipsychotic by to the twice-yearly for schizophrenia, and we the for treatment interval our for full medication XX% makes schizophrenia pipeline have an be European to available with antipsychotic commitment billion dosing This received in first is the the a $X.X adult
the RYBREVANT, treatment marketing first with targeting for conditional Additionally, Exon non-small of after authorization therapy cell bispecific approved XX platinum-based a RYBREVANT with and mutations failure patients lung cMet, EMEA. cancer received EGFR in EGFR therapy. insertion is both
intelligence assessing portfolio to the care BCMA in with an off-the-shelf safety to refractory to targeting for a Teclistamab expand options or approval study more Devices and collaboration the further with collaboration the now the and both did over CDX. Johnson as generate concludes digital of call the sales develop for our Biologics study solutions This meet portfolio. help antibody personalized the connecting teclistamab order as redirecting insights care quarter are Finally, of therapy less treatment goal treatment U.S. prioritization, the patients we to & Joe its full is multiple of am devices continuum. a Application License myeloma use investigational add-on highlights strategic enhance secure point. Consistent pleased FDA the across as of standard announced Microsoft primary across entire patient leading strategy inoperable patients. our bispecific Wolk. of we compliant an turn submitted to discontinuing to disciplined and selexipag entire in for T-cell with This multiple the and Phase efficacy not approach and X a smarter, machine myeloma to XXXX. to year CTEPH, aligned patients of and relapsed with SELECT end artificial with Medical invasive P&L with the seeking the ecosystem to and Johnson's and learning fourth I a will
